Drug Profile
Polyhexamethylene biguanide
Latest Information Update: 23 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Biguanides; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Keratomycosis
Most Recent Events
- 07 Sep 1999 New profile
- 07 Sep 1999 Preclinical development for Keratomycosis in USA (Topical)